Calamos Convertible Opportunities and Income Fund (CHI) and Calamos Convertible and High Income Fund (CHY) hold nearly identical portfolios but trade at significantly different prices. CHI trades at a 1.88% premium while CHY trades at a 3.86% discount, creating a 5.74-point gap well above the usual range. This divergence offers investors a chance to buy CHY at a discount with a higher yield and potentially profit by shorting CHI and going long on CHY. The funds’ high correlation in NAV movements supports this arbitrage strategy for advanced investors.
The story about Calamos Convertible Opportunities and Income Fund (CHI) and Calamos Convertible and High Income Fund (CHY) is presented with market context from Pluang's Financials sector. For readers following this sector, here is Pluang's market snapshot as of Oct 07, 2026 02:11 WIB: out of 85 priced Financials-sector US stocks, 53 rose and 31 fell. Notable movers include Blackrock Inc (BLK) at USD 1,083.48 with a 1.60% increase and Sezzle Inc (SEZL) at USD 112.49 with a 1.48% increase.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
